Detalhes bibliográficos
Ano de defesa: |
2009 |
Autor(a) principal: |
VIEIRA, Marcelo de Sousa
 |
Orientador(a): |
BOZINIS, Marize Campos Valadares
 |
Banca de defesa: |
Não Informado pela instituição |
Tipo de documento: |
Dissertação
|
Tipo de acesso: |
Acesso aberto |
Idioma: |
por |
Instituição de defesa: |
Universidade Federal de Goiás
|
Programa de Pós-Graduação: |
Mestrado em Ciências da Saúde
|
Departamento: |
Ciências da Saúde - Medicina
|
País: |
BR
|
Palavras-chave em Português: |
|
Palavras-chave em Inglês: |
|
Área do conhecimento CNPq: |
|
Link de acesso: |
http://repositorio.bc.ufg.br/tede/handle/tde/1715
|
Resumo: |
The animal replacement in expirements has been very encouraged by government and other institutions. However, in drugs development the animal replacement is not yet a reality, like at oral acute systemic tests. The validation of in vitro protocols is necessary for data generation with reproducibility, repetability and accuracy. In this study was validated at the Laboratório de Farmacologia e Toxicologia Celular- Faculdade de Farmácia/Universidade Federal de Goiás the protocol already validated by three laboratories (two in the USA and one at United Kingdom) and coordinated by ICCVAM: In Vitro Cytotoxicity Methods for Estimating Starting Doses for Acute Systemic Toxicity Tests, using the neutral red uptake in BAL/c 3T3-A31 cell line. It was used the grandisine, a lignan, and its major metabolite taken by fungi biodegradation. Our research group has identified a potential anti-tumoral action of grandisine, data not yet published. After in house validation we estimated the LD50 of grandisin and 4-O-demethylgrandisin: 617.72 mg/kg and 429.95 mg/kg, respectively. Both were classified under the GSH category 4. |